Internal Reference Number: FOI_6478
Date Request Received: 17/02/2022 00:00:00
Date Request Replied To: 09/03/2022 00:00:00
This response was sent via: By Email
Request Summary: Lung Cancer Medication
Request Category: Researcher
| Question Number 1: In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with: • Afatinib • Alectinib • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Bevacizumab • Brigatinib • Ceritinib • Crizotinib • Dacomitinib • Dabrafenib with Trametinib • Docetaxel monotherapy or combination with Carboplatin/Cisplatin • Durvalumab • Erlotinib • Gefitinib • Gemcitabine • Lorlatinib • Nintedanib with Docetaxel • Nivolumab • Osimertinib • Paclitaxel • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Pemetrexed with Carboplatin/Cisplatin • Tepotinib • Vinorelbine with Carboplatin/Cisplatin • Any other active systemic anti-cancer therapy (SACT) • Palliative care only | |
| Answer To Question 1: Afatinib 0 Alectinib <5 Atezolizumab mono <5 Zero each for atezolizumab with chemo, bevacizumab, brigatinib, ceritinib Crizotinib <5 Zero each for dacomitinib, dabarfenib with trametinib, docetaxel mono or combination Durvalumab <5 Erlotinib 0 Gefitinib <5 Gemcitabine 0 Lorlatinib <5 Nintedanib with docetaxel 0 Nivolumab 0 Osimertinib 10 Paclitaxel 0 Pembrolizumab mono 11 Pembrolizumab with chemo <5 Pemetrexed with carb/cisplatin <5 Tepotinib 0 Vinorelbine with carb/cisplatin <5 Other SACT 7 Unable to answer about palliative care only | |
| Question Number 2: In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs: • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Durvalumab • Gemcitabine • Nivolumab • Osimertinib • Paclitaxel • Pembrolizumab (Keytruda) Mono • Pembrolizumab (Keytruda) with Chemotherapy • Other active systemic anti-cancer therapy (SACT) • Palliative care only | |
| Answer To Question 2: Atezolizumab mono 0 Atezolizumab with chemo <5 Durvalumab <5 Zero each Gemcitabine , nivolumab, osimertinib, paclitaxel, pembrolizumab with chemo Pembrolizumab mono <5 Other SACT 0 Palliative only unable to answer | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
